Founder, Senior Research Adviser
Xenetic Biosciences Inc.
Professor Gregory Gregoriadis is the Founder (1997) of Xenetic Biosciences Inc, the creator of the company's PolyXen (polysialic acid) and ImuXen (liposome) technologies and a SAB member. He served as a Board member, Director and CSO (1997-2015). He was Head of the Centre for Drug Delivery Research(1990-2001) at University College London, and Head of the Liposomes Group at the Medical Research Council (1972-1990). In 1971 he introduced(with B. Ryman) liposomes for drug and vaccine delivery, and in 1991 introduced polysialic acid to improve the pharmacokinetics and pharmacodynamics of protein and peptide drugs. He has published nearly 400 research papers, reviews and articles, and 27 books on drug and vaccine delivery. Gregory's achievements have been honoured with the Controlled Release Society Founders Award (1994), the A.D. Bangham FRS Life Achievement Award (1995), a Fellowship in the American Association of Pharmaceutical Scientists (1998), a Fellowship in the Controlled Release Society(2013), a DSc from the University of London (2001), a Journal of Drug Targeting Life Achievement Award (2008), a Fellowship in the Academy of Pharmaceutical Scientists (2008), and the Founders Award of Liposome Research Days (2010), all for exceptional contributions to the field of drug and vaccine delivery. Gregory's seminal contributions are also reflected in his founding (1978) of the Gordon Research Conference series 'Drug Carriers in Medicine and Biology', his directorships of the NATO Advanced Studies Institute series 'Drug Targeting' and 'Vaccines' (1981-1999), his founding of the 'Liposome Advances' conference series (1991-2013), and his position of Professor Emeritus at University College London. He is in charge of the International Liposome Society(since 2003).
Drug Delivery Research